<br> <br><p>ADB-FUBINACA and AMB-FUBINACA are two artificial indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold stronger, respectively, than trans-∆9-tetrahydrocannabinol (∆9-THC), the principle psychoactive compound of cannabis. Synthesised in as a pharmaceutical drug candidate, the leisure use of ADB-FUBINACA was first reported in 2013 in Japan, with deadly circumstances being described in 2015. ADB-FUBINACA is among the most apprehended and consumed artificial cannabinoid , following AMB-FUBINACA, which emerged in 2014 as a drug of abuse and has since been responsible for several intoxication and death outbreaks. Here, we critically evaluation the physicochemical properties, detection strategies, prevalence, biological results, pharmacodynamics and pharmacokinetics of each medicine. When</p><br><br>